Background and Aims: this study was undertaken in order to evaluate the usefulness of the euroscore in the choice and outcome of mitral valve procedures undertaken at the helsinki university central hospital.
light the liability of the procedurei nv arious situations (1, 2, 3). The main purpose of this study was to evaluate the type and results of mitral valve procedures undertaken using the European System for Cardiac Operative Risk, and to contribute to the discussion on how this scoring system can effect the choice of procedure-i .e. whether to repair or replace.
MATERIAL AND METHODS
The data of 378 patients operated on between January 1999 and December 2003 at Helsinki University Central Hospital was collected retrospectively,2 27 patients had undergone MVP and 151 MVR. Carpentier techniques wereu sed in INTRODUCTION Therehas been apivotal change in mitral valve operations, with am ove from mitral valve replacement (MVR) to mitral valve repair (MVP) over the last few decades. Several studies have already reported convincing long-term results with MVP's which high-mitral valve repair (4)-including aquadrangular resection and sliding-technique in posterior leaflet operations, atriangular resection in anterior leaflet, ring annuloplasty, chordal-shortening, artificial chords and chordal-replacements. Additional methods used werec losureo fc lefts, a widening of the anterior leaflet with ap ericardium-patch and support of the annulus with a posterior Gore-Tex-band. Both biological and mechanical prostheses wereu sed to replace the valve. In addition, surgery for atrial fibrillation was performed on 26 patients (5). Simultaneous coronary artery bypass grafting (CABG), aortic valve replacement (AVR) and/or tricuspid valve operations werep erformed as needed. Vancomysin 1g and kefuroxime 1.5g weregiven at the beginning of anaesthesia and 8hours later as an antibiotic prophylaxis. Low molecular weight heparin was given postoperatively until INR values werea tt he treatment level after the beginning of warfarin treatment. Patients in sinus rhythm who had MVP or MVR with biological valve weret reated with warfarin for three months postoperatively,while those with atrial fibrillation and/or who had MVR with mechanical prostheses take warfarin for life. Complications included infections, valve-related problems (valve regurgitations or paravalvular leakage), haemorrhage, transient neurological disorders (TIA, delayed wakening, convulsions, deterioration, confusion, agitation) and permanent neurological disorders (stroke, hypoxic ischemic encephalopathy,p araplegia). Diagnoses weremade by aneurologist and was completed by CT-scan or other neurological interventions according to aneurologist. The length of ICU and hospital stay was recorded. Transthoracic or transesophageal echo was used to assess heart function and postoperative result, cardiac rhythm was recorded and the MB-fraction of creatine kinase (s-CK-MB) was measured postoperatively.
STATISTICAL ANALySIS:
We calculated risk factors for all patients using the Euroscoreand compared them to actual 30-day mortalities (6). To define the possible change in the choice of mitral valve procedures during the followed period, we made ay earby-year study of mortality rates, risk and lengths of postoperative hospital stay.T he Kaplan-Meier method was used to draw up survival curves. Statistical analyses were carried out using the SPSS 12.0.1 for Windows program package. Student's t-test was used for comparative statistics of normally distributed data, and the Mann-Whitney U-test for non-normally distributed data. Fischer's exact test was applied in analysing the incidence of mortality and complications. .
RESULTS
Preoperative data has been collected into Table 1 . Three hundred and seventy-eight (239 male and 139 female) patients wereo perated during this time period. Although left ventricle ejection fraction (EF) did not differ between the two groups, patients in the MVR group had significantly higher mean systolic pulmonary artery pressures (syst. pPA) .
Of the mitral valve plasties (MVP) performed, the posterior leaflet alone was repaired in 56.3%, and the anterior leaflet alone in 15.3%. The sliding-technique was used in 20.5% of theposterior leaflet procedures. An anterior leaflet was repaired with simultaneous aortic root reconstruction by homograft in one patient, and pericardium patches wereused in 13 cases of anterior leaflet repair.B oth leaflets werer epaired in 11.3% of the cases. In 17.1% of the patients ring annuloplasty only was performed. Of the valve replacement operations (MVR) performed, biological prostheses wereused in 44.7% of the cases. Simultaneous CABG was performed in 31.3% (71) of the MVP group and 34.4% (52) of the MVR group. Aconcomitant aortic valve operation was performed in 10.6% (40) of the operations, and at ricuspid valve proce-durein5.3%(22), respectively.Surgery for atrial fibrillation was performed simultaneously with mitral valve operations in 7.5% (17) of the MVP group and in 6.0% (9) of the MVR group in order to restores inus-rhythm. MVP was performed on 10 (59%) and MVR on 7(41%) patients with endocarditis. The presence of ac alcified annulus was am ajor determinant for choosing the procedure. More than 24.4% of the patients in the MVR group had annulus calcification, but only 5.9% in the MVP group. Table 1. Overall mortality was 3.5% for MVP operations and 13.9% for MVR operations. Ag radual decrease was observed in the mortality rate of MVP group from 1999 to 2003 (Table 2) . Simultaneously,the mean logistic EuroSCORE at first increased up to 2001 and then decreased in 2003. The difference between predicted and actual mortality became morefavourable for MVPp atients,w hilet he mortality in theM VR group displayed am uch wider variation (Table 3) . Nevertheless, apart from in 2001, thereh as been a notable rise in the mean logistic EuroSCORE among patients chosen for MVR between 1999 and 2003 by almost two percentage units.
The mortality in MVP and MVR procedures without CABG was lower than predicted (Table 4 ). The mortality in MVP operations combined with CABG was within its expected range. In contrast, the mortality in MVR operations was much higher then expected.
The mean length of ICU-stay for MVP patients increased initially during the period from 1999 to 2001, but then decreased to below its starting level by 2003. The average hospital stay had also decreased by the end of 2003. The averagelengths of ICU and hospital stay for MVR patients has varied agood deal, andalthough they haved ecreased overall-they were slightly higher at the end of the follow-up period than at the beginning.
Patients in the MVR group had less transient neurological disorders and haemorrhages than those in the MVP group (Table 5 ). The amount of permanent neurological disorders and valve related problems was the same in both groups. Furthermore, patients in the MVR group suffered morei nfections and reoperations. Although, statistically could only be found within infections and mortality of patients with predicted preoperative mortality rates of 5-10%. The differences werei nf avour of the patients in the MVPgroup. All patientswith endocarditiswho were operated on survived. Atotal of 12.3% of the patients in the MVP group and 16.6% of the patients in the MVR group had postoperative CK-MB levels over 100 µ/ml. The mean EF decreased peri-operatively in 7.1% (MVP) and 5.9 (MVR), respectively.Inthe MVP group, 71.7% of the patients had sinus-rhythm pre-operatively.Ofthese, 57.0% had atrial fibrillation at discharge, while in the MVR group 64.5% of the patients who had preoperatively been in sinus-rhythm had atrial fibrillation as apost-operative complication Eight (47.1%) of the 17 patients in the MVP group, who had had as imultaneous MAZE-procedureh ad sinus-rhythm when leavingh ospital. In the MVR group, two (22.2%) of the nine patients had sinusrhythm at the end of the hospital care, six had atrial fibrillation and one died during surgery.
In the MVP group, eight patients (3.5%) operated on between 1999 and 2003 required asubsequent reoperation of the valve. Twoofthem had re-MVP and six underwent MVR. In addition four other patients operated on before1 999 werei ncluded in the valve repair reoperation group. In the MVR group, seven (4.6%) patients needed ar e-operation. Overall, 26 (17.2%) of the MVR procedures werer e-operations due to previous MV plasty (12) or MV replacement (14).
The survival curve displayed ah igher mortality rate in the MVR group than in the MVP group during the first postoperative year,80% versus 92%. At three years the survival rates were7 4% and 89%, respectively.F ive-year survival was 86.6% in the MVP group and 69.8% in the MVR group (Fig. 1 ).
DISCUSSION
Thereh as been ac hange in the procedureo fchoice during the study period, over which time our teams have moved towards repairing the mitral valve without prosthesis. Beforet he year 2000, MVR was the first choice for treating patients with mitral valve failures, but after this thereh ave been morer epair operations performed annually.T he MVP/MVR ratio has now settled at ar ate of 9:1 (MVP/MVR). The good results obtained have encouraged us to operate ever morecomplex cases of mitral failures. The actual mortality in both the MVP and MVR groups was close to the predicted mortality risk for the procedure. In single MVP and MVR procedures the risk calculator overestimates the logistic risk for 30-day mortality.O ther than isolated coronary surgery,e ach surgical proceduret ends to increase the predicted risk by 0.63 percentage units. The mortality for the MVP +CABG group was in the expected range. The combined surgery with prosthetic valve increased the actual mortality much higher than expected. The numbers of cases weref ew and the patientsw erei nw orse conditiont hanM VP patients preoperatively.ICU stay was somewhat prolonged in our hospital compared to data from other studies (7, 8, 9) . The reason for this being that therei sn os tepdownunit in our hospital. If patientsrequirerhythm observation or observation for another reason, they thereforeneeded to be on the ICU.
The exceptionally high (35 %) mortality in the MVR group in 2001 can be partially explained by the following factors: First, we had only 17 patients undergoing MVR that year (compared to over 30 patients for every other year). Second, these patients wereat avery high risk, with amean logistic EuroSCORE of 18.1%. Third, although the length of the hospital stay in the MVR group rose from that in 2000 to 2001, the length of ICU stay fell. This suggests that the patients who underwent MVR in 2001 werei np oor preoperative condition and they either died during or almost instantly after surgery,o rr equired long recovery periods in the hospital.
When the two different operation methods were compared, we found that the mortality for the MVR group was nearly four times higher than for the MVP group. However,the patients in the MVR group had almost double the higher preoperative risk points. Although the patients in the MVR group had acalcified annulus nearly five times moreo ften then patients in the MVP group, therew as no difference in the incidence of permanent neurological disorders. Indeed, the patients in the MVR group had significantly less transient neurological disorders. The high mortality rate in the MVR group may also conceal a higher incidence of neurological complications. The five-year survival was higher in MVP group, as has previously been shown in other studies (10, 11) .
The benefits of MVP and biological valve prostheses compared to mechanical prostheses aret he lack of lifelong warfarin treatment. As biological valve prostheses tend to degenerate, however,t hese patients may need to have are-operation within amean of 15 years (12) . Therefore, mechanical prostheses are favoured in patients under 65 years of age who need to undergo MVR.
In conclusion, the decreased mortality rate and the decreased lengths of both ICU and hospital stay of the patients in the MVP group showed that the results of mitral valve repair procedures have improved during the study period and continue to improve. The decreased mortality rates of the MVR patients together with their increased Euroscorepoints demonstrated how the technique of mitral valve replacement procedures has improved. Mitral valve surgery should be concentrated amongst as small an umber of surgeons as possible in order to maintain quality.
The low mortality rate, low incidence of complications, low frequency of re-operations, the short periods of hospital stay and the good middle-term survival confirm that MVP is asafe method for treating patients who have mitral valve diseases with less severes ymptoms, as estimated by EuroSCORE. The treatment of these patients with MVP allows us to use the MVR procedures only in patients in moresevere preoperative condition.
